The differential response to immune checkpoint inhibitors in colorectal and endometrial cancer patients according to different mismatch repair alterations


Moh’d M. Khushman, Michael Driscoll Toboni, Jia Zeng, Joanne Xiu, Upender Manne, Alex Farrell, Bassel El-Rayes, Emil Lou, Anthony Frank Shields, Philip Agop Philip, Mohamed E. Salem, Jim Abraham, David Spetzler, John Marshall, Priya Jayachandran, Michael J. Hall, Heinz-Josef Lenz, Wolfgang Michael Korn, Matthew A. Powell

Key Finding:

  • In colorectal cancer patients, median overall survival and median overall survival in response to immune checkpoint inhibition is longer in patients with intact MLH1 and PMS2 and co-loss of MSH2 and MSH6 (MutS) versus co-loss of MLH1 and PMS2 and intact MSH2 and MSH6 (MutL). 
Download Publication